News related to Prevacid (Lansoprazole) and/or conditions it is approved for
Mylan Receives FDA Approval For Generic Version Of Prevacid® Through Its Subsidiary Matrix Laboratories
Source: GastroIntestinal / Gastroenterology News From Medical News Today [2009.11.12]
Mylan Inc. (NASDAQ: MYL) announced that its privately held Indian subsidiary, Matrix Laboratories Limited, has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Lansoprazole Delayed-release (DR) Capsules, 15 mg and 30 mg. This product is shipping immediately and will be sold under the Mylan Pharmaceuticals brand.
Teva Receives Favorable Court Decision Regarding Generic Prevacid(R) SoluTab
Source: Litigation / Medical Malpractice News From Medical News Today [2009.11.11]
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. District Court for the District of Delaware has issued a decision in its litigation over the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Takeda Pharmaceuticals North America, Inc.'s Prevacid® (Lansoprazole) SoluTab. The Court found that Teva's generic lansoprazole orally disintegrating tablets do not infringe U.S. Patent No. 5,464,632.
|
